{"id":"l-serine","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal disturbance"},{"rate":null,"effect":"Nausea"}]},"_chembl":null,"_dailymed":{"setId":"3e8a9233-6e65-4023-b3f8-8bca369a9c2a","title":"VITAL SKIN HAIR NAILS (L-ALANINE, L-ARGININE, L-CARNITINE, CYSTEINUM, L-GLUTAMINE, L-HISTIDINE, L-ISOLEUCINE, L-LEUCINE, L-LYSINE, L-METHIONINE, L-ORNITHINE, L-PROLINE, L-SERINE, L-TRYPTOPHAN, L-TYROSINE, L-VALINE, APIS MELLIFICA, BIOTIN, EPIDERMIS SUIS, GALIUM APARINE, HAMAMELIS VIRGINIANA, HEPAR SUIS, HGH, HYPOPHYSIS SUIS, NATRUM MURIATICUM, PANTOTHENIC ACID, PHOSPHORICUM ACIDUM, RIBOFLAVINUM, THUJA OCCIDENTALIS) SPRAY [LIDDELL LABORATORIES, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"L-Serine is a proteinogenic amino acid that acts as a building block for proteins and as a precursor for the synthesis of sphingolipids, phosphatidylserine, and the neurotransmitter glycine. It plays critical roles in nervous system development, myelin formation, and cellular signaling. L-Serine supplementation is used to address deficiencies in serine synthesis or metabolism, particularly in neurological conditions.","oneSentence":"L-Serine is a non-essential amino acid that serves as a precursor for neurotransmitter and phospholipid synthesis, supporting neurological function and cell membrane integrity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:49:12.048Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Serine deficiency disorders"},{"name":"Neurological support in various conditions"}]},"trialDetails":[{"nctId":"NCT07497347","phase":"NA","title":"Effects of Specific Amino Acid Supplementation and Lifestyle Factors on Brain Ageing","status":"RECRUITING","sponsor":"IRCCS Centro San Giovanni di Dio Fatebenefratelli","startDate":"2026-03-01","conditions":"Late-Life Depression","enrollment":84},{"nctId":"NCT07471256","phase":"PHASE3","title":"Neuronavigation-assisted Stereotactic Minimally Invasive Puncture With Tenecteplase for Acute Lobar Intracerebral Hemorrhage","status":"NOT_YET_RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2026-03-31","conditions":"Intracerebral Hemorrhage Lobar","enrollment":636},{"nctId":"NCT05387954","phase":"PHASE3","title":"PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-07-07","conditions":"Cryptogenic Ischemic Stroke, Patent Foramen Ovale","enrollment":792},{"nctId":"NCT07340541","phase":"PHASE2","title":"Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies","status":"NOT_YET_RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2026-02","conditions":"Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer","enrollment":700},{"nctId":"NCT04278768","phase":"PHASE1, PHASE2","title":"Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)","status":"SUSPENDED","sponsor":"Curis, Inc.","startDate":"2020-07-06","conditions":"Acute Myelogenous Leukemia, Myelodysplastic Syndrome","enrollment":366},{"nctId":"NCT07253181","phase":"PHASE3","title":"Tenecteplase Before Interhospital Transfer for EVT in Acute Anterior Circulation LVO at 4.5-24 Hours","status":"RECRUITING","sponsor":"Xuanwu Hospital, Beijing","startDate":"2026-01-06","conditions":"Acute Ischemic Stroke, Large Vessel Occlusion, Transportation of Patients","enrollment":572},{"nctId":"NCT07263022","phase":"PHASE3","title":"Cognitive Strategies in Early Psychosis 2","status":"NOT_YET_RECRUITING","sponsor":"University of Minnesota","startDate":"2026-04-13","conditions":"Psychosis, Schizophrenia Disorder, Schizoaffective Disorder","enrollment":24},{"nctId":"NCT07476898","phase":"PHASE3","title":"Precision Reperfusion Therapy for Disabling Minor Stroke With Large Vessel Occlusion Beyond Time Window","status":"NOT_YET_RECRUITING","sponsor":"First Hospital of China Medical University","startDate":"2026-03-01","conditions":"Stroke","enrollment":864},{"nctId":"NCT07361302","phase":"PHASE3","title":"A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well","status":"RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2026-02-17","conditions":"Acute Ischemic Stroke","enrollment":1325},{"nctId":"NCT07475949","phase":"PHASE3","title":"Unknown Time of Onset Stroke RePerfusIon Without Advanced Imaging","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Guangxi Medical University","startDate":"2026-04","conditions":"Acute Ischemic Stroke, Tenecteplase","enrollment":352},{"nctId":"NCT07475936","phase":"","title":"Intravenous Tenecteplase in Very Old Patients With Acute Ischemic Stroke","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Guangxi Medical University","startDate":"2026-04","conditions":"Acute Ischemic Stroke, Tenecteplase","enrollment":392},{"nctId":"NCT05521438","phase":"PHASE2, PHASE3","title":"Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Quoin Pharmaceuticals","startDate":"2022-06-23","conditions":"Netherton Syndrome","enrollment":30},{"nctId":"NCT07471282","phase":"PHASE3","title":"Reperfusion Completion Via Local Arterial Infusion of Tenecteplase After Incomplete Mechanical Thrombectomy","status":"NOT_YET_RECRUITING","sponsor":"Chuansheng Zhao","startDate":"2026-03-01","conditions":"Stroke","enrollment":344},{"nctId":"NCT05491356","phase":"PHASE4","title":"Use of Tissue Plasminogen Activator in the Clearance of Chronic Subdural Hematomas","status":"COMPLETED","sponsor":"Hamilton Health Sciences Corporation","startDate":"2023-05-11","conditions":"Hematoma, Subdural, Fibrinolytic; Hemorrhage","enrollment":40},{"nctId":"NCT07466290","phase":"NA","title":"L-serine and Strength Training in the Elderly","status":"RECRUITING","sponsor":"University of Vienna","startDate":"2026-03","conditions":"Brain Health, Longevity, Cognitive Performance","enrollment":126},{"nctId":"NCT04640610","phase":"","title":"Angiotensin-converting Enzyme 2 (ACE2) Expression in Tonsils and Adenoids","status":"WITHDRAWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-06-30","conditions":"Adenoidectomy, Tonsillectomy","enrollment":""},{"nctId":"NCT07460947","phase":"PHASE1, PHASE2","title":"A Pilot Trial of One-Day Accelerated TMS and D-cycloserine in Suicidal Patients With Borderline Personality Disorder","status":"NOT_YET_RECRUITING","sponsor":"Mclean Hospital","startDate":"2026-03","conditions":"Borderline Personality Disorder (BPD)","enrollment":20},{"nctId":"NCT05514132","phase":"PHASE1","title":"A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2022-09-23","conditions":"Advanced Solid Tumours","enrollment":14},{"nctId":"NCT07432373","phase":"","title":"Intrapleural Alteplase-Tyloxapol vs Intrapleural Alteplase-DNase in Pleural Infection","status":"NOT_YET_RECRUITING","sponsor":"National University of Malaysia","startDate":"2026-04-01","conditions":"Pleural Infection","enrollment":80},{"nctId":"NCT03780829","phase":"EARLY_PHASE1","title":"AIH for Spinal Cord Repair","status":"TERMINATED","sponsor":"VA Office of Research and Development","startDate":"2020-02-25","conditions":"SCI","enrollment":50},{"nctId":"NCT04874428","phase":"PHASE1","title":"Direct Oral Anticoagulants (Rivaroxaban and Apixaban) in Patients With Liver Cirrhosis","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2021-05-19","conditions":"Liver Cirrhosis","enrollment":24},{"nctId":"NCT05903417","phase":"NA","title":"Pleural Irrigation With Normal Saline Versus Intrapleural Fibrinolytic","status":"COMPLETED","sponsor":"National University of Malaysia","startDate":"2023-07-10","conditions":"Pleural Infection","enrollment":40},{"nctId":"NCT07343960","phase":"PHASE1","title":"A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2026-01-06","conditions":"Moderate Hepatic Impairment","enrollment":20},{"nctId":"NCT06241677","phase":"NA","title":"Intravenous Thrombolytic Therapy in Acute Ischemic Stroke Patients on DOAC","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2024-04-15","conditions":"CVA (Cerebrovascular Accident)","enrollment":260},{"nctId":"NCT07429227","phase":"NA","title":"Evaluation Through Innovative Examinations of Intestinal Dysbiosis Status in Patients Diagnosed With Cardiovascular Diseases and Evaluation of the Efficacy of Natural and Probiotic Extracts in the Non-pharmacological Approach to Improving Intestinal Dysbiosis Status.","status":"RECRUITING","sponsor":"Casa di Cura Dott. Pederzoli","startDate":"2026-03","conditions":"Acute Coronary Syndromes (ACS)","enrollment":15},{"nctId":"NCT06694753","phase":"PHASE1","title":"Safety and Immunogenicity Study of Three mRNAs Encoding HIV Immunogens in Adult Participants Without HIV and in Overall Good Health in South Africa.","status":"RECRUITING","sponsor":"International AIDS Vaccine Initiative","startDate":"2025-12-15","conditions":"HIV Infections","enrollment":96},{"nctId":"NCT07375953","phase":"PHASE2","title":"Repeated Intravenous Thrombolysis for Ischemic Stroke Within 3.0 Hours of Onset With Tenecteplase (RITIS-TNK)","status":"NOT_YET_RECRUITING","sponsor":"General Hospital of Shenyang Military Region","startDate":"2026-03-01","conditions":"Ischemic Stroke","enrollment":120},{"nctId":"NCT07375966","phase":"PHASE2","title":"Repeated Intravenous Thrombolysis for Ischemic Stroke With Medium to Large Vessel Occlusion Presenting Within 4.5 Hours of Onset With Tenecteplase (RITIS-TNK2)","status":"NOT_YET_RECRUITING","sponsor":"General Hospital of Shenyang Military Region","startDate":"2026-03-01","conditions":"Ischemic Stroke","enrollment":198},{"nctId":"NCT05701956","phase":"PHASE3","title":"Intravenous Tenecteplase Plus EVT Versus EVT Alone on 4.5 to 24 Hours After Basilar Artery Occlusion","status":"COMPLETED","sponsor":"The First Affiliated Hospital of University of Science and Technology of China","startDate":"2023-03-16","conditions":"Basilar Artery Occlusion, Acute Cerebrovascular Accident, Stroke Due to Basilar Artery Occlusion","enrollment":330},{"nctId":"NCT07398508","phase":"PHASE1, PHASE2","title":"Phase I/II Study of NORTHERA (DROXIDOPA) for Dysautonomia in Pediatric Survivors of Menkes Disease.","status":"RECRUITING","sponsor":"Stephen G. Kaler","startDate":"2026-06-01","conditions":"Menkes Disease","enrollment":6},{"nctId":"NCT05499832","phase":"PHASE3","title":"Safety and Efficacy of Intra-arterial Tenecteplase for Noncomplete Reperfusion of Intracranial Occlusions","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2023-03-21","conditions":"Ischemic Stroke","enrollment":156},{"nctId":"NCT06863545","phase":"NA","title":"Further Lipid-Lowering With PCSK9 Inhibitors for Cardiovascular Outcomes in High-Risk Coronary Plaques Assessed by CT Angiography","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-04-22","conditions":"Coronary Artery Disease, CT Angiography, PCSK9","enrollment":3596},{"nctId":"NCT07079930","phase":"PHASE1","title":"Safety and Psychological Effects of Psilocybin and D-Serine Formulation in Healthy Volunteers","status":"RECRUITING","sponsor":"Hadassah Medical Organization","startDate":"2025-12-11","conditions":"Healthy Volunteers","enrollment":10},{"nctId":"NCT04663750","phase":"PHASE3","title":"Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER).","status":"RECRUITING","sponsor":"King's College Hospital NHS Trust","startDate":"2021-04-16","conditions":"Eye Diseases, Macular Degeneration, Wet, Sub-Macular Hemorrhage","enrollment":210},{"nctId":"NCT07255742","phase":"NA","title":"Role of Lactoferrin in Prevention of Ventilator Associated Pneumonia in Neonates.","status":"COMPLETED","sponsor":"Dalia Mohamed Salah","startDate":"2025-08-01","conditions":"Ventilator Associated Pneumonia","enrollment":50},{"nctId":"NCT07374978","phase":"NA","title":"Effect of Thrombolysis on 30-day Mortality in Intermediate High Risk Pulmonary Patients With Low Bleeding Risk","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2023-07-01","conditions":"Pulmonary Embolism Subacute Massive, Thrombolytic Therapy","enrollment":100},{"nctId":"NCT07377032","phase":"PHASE3","title":"TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders","status":"RECRUITING","sponsor":"Meyer Children's Hospital IRCCS","startDate":"2025-08-29","conditions":"GRIN-related Disorders, GRIN1, GRIN2A","enrollment":40},{"nctId":"NCT03947385","phase":"PHASE1, PHASE2","title":"Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions","status":"RECRUITING","sponsor":"IDEAYA Biosciences","startDate":"2019-06-28","conditions":"Metastatic Uveal Melanoma, Cutaneous Melanoma, Colorectal Cancer","enrollment":336},{"nctId":"NCT07360717","phase":"NA","title":"To Compare the Efficacy & Safety of Ultra-Slow (24 hr) Low Dose (25 mg) Infusion of Alteplase Over Slow (24hr) Infusion of Streptokinase in Mechanical Prosthetic Valve Thrombosis","status":"COMPLETED","sponsor":"U. N. Mehta Institute of Cardiology and Research Center","startDate":"2024-11-01","conditions":"Thrombolysed","enrollment":100},{"nctId":"NCT06658197","phase":"PHASE3","title":"Efficacy and Safety of Tenecteplase Bridging Mechanical Thrombectomy for Acute Large Vessel Occlusion Stroke","status":"RECRUITING","sponsor":"Xuanwu Hospital, Beijing","startDate":"2025-12-25","conditions":"Stroke, Ischemic, Stroke, Acute, Thrombosis, Brain","enrollment":850},{"nctId":"NCT06310018","phase":"","title":"Augmented Ultrasound-Facilitated, Catheter-Directed Fibrinolysis for PE","status":"SUSPENDED","sponsor":"Brigham and Women's Hospital","startDate":"2027-01-01","conditions":"Pulmonary Embolism, Right Ventricular Dysfunction, Right Ventricular Failure","enrollment":60},{"nctId":"NCT07003646","phase":"","title":"Reperfusion Treatment in Acute Pulmonary Embolism","status":"RECRUITING","sponsor":"Sahlgrenska University Hospital","startDate":"2025-04-01","conditions":"Pulmonary Embolism","enrollment":220},{"nctId":"NCT06949228","phase":"PHASE2, PHASE3","title":"Adjunctive Intra-arterial Tenecteplase Following Mechanical Thrombectomy (ALLY) II Trial","status":"RECRUITING","sponsor":"ProMedica Health System","startDate":"2025-07-30","conditions":"Ischemic Stroke, Acute Disease","enrollment":132},{"nctId":"NCT04679259","phase":"NA","title":"Evaluation of Blood Biomarkers as an Indicator of Delayed Neurocognitive Recovery","status":"COMPLETED","sponsor":"SMG-SNU Boramae Medical Center","startDate":"2021-01-06","conditions":"Postoperative Cognitive Dysfunction","enrollment":82},{"nctId":"NCT07352358","phase":"PHASE4","title":"Randomized Trial of Anticoagulation Plus Batroxobin for Acute Cerebral Venous Thrombosis","status":"RECRUITING","sponsor":"Xuanwu Hospital, Beijing","startDate":"2026-01-30","conditions":"Cerebral Venous Thrombosis","enrollment":72},{"nctId":"NCT05994703","phase":"PHASE2","title":"Assisting Smokers to Switch to an e-Cigarette by Accelerating Learning of Adaptive Habits Using D-cycloserine","status":"COMPLETED","sponsor":"Rose Research Center, LLC","startDate":"2023-10-20","conditions":"Smoking Cessation, Harm Reduction","enrollment":25},{"nctId":"NCT07342439","phase":"PHASE3","title":"Study of Serine Supplementation to Protect Vision in MacTel","status":"NOT_YET_RECRUITING","sponsor":"The Lowy Medical Research Institute Limited","startDate":"2026-09","conditions":"Macular Telangiectasia Type 2 (MacTel)","enrollment":120},{"nctId":"NCT05050084","phase":"PHASE3","title":"Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2021-12-06","conditions":"Prostate Adenocarcinoma","enrollment":2050},{"nctId":"NCT04513717","phase":"PHASE3","title":"Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"NRG Oncology","startDate":"2021-01-21","conditions":"Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8","enrollment":2753},{"nctId":"NCT05826964","phase":"PHASE2","title":"Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2023-06-12","conditions":"Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer","enrollment":24},{"nctId":"NCT03328273","phase":"PHASE1","title":"A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Acerta Pharma BV","startDate":"2018-01-31","conditions":"Chronic Lymphocytic Leukemia","enrollment":12},{"nctId":"NCT04647227","phase":"PHASE4","title":"SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors","status":"RECRUITING","sponsor":"American Thrombosis and Hemostasis Network","startDate":"2021-06-28","conditions":"Hemophilia A With Inhibitor, Hemophilia B With Inhibitor","enrollment":55},{"nctId":"NCT02069730","phase":"NA","title":"A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2014-06","conditions":"Salivary Gland Cancer, Metastatic, Advanced","enrollment":114},{"nctId":"NCT07271342","phase":"","title":"Observational RegIstry of Effectiveness and Safety of teNecTeplase in reAl worLd Settings in China","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2025-11-30","conditions":"Stroke","enrollment":10000},{"nctId":"NCT07312110","phase":"PHASE2","title":"D-SPARK: A Clinical Trial of D-Serine for Modifying Parkinson's Disease Progression","status":"RECRUITING","sponsor":"Haukeland University Hospital","startDate":"2026-01","conditions":"Parkinson s Disease, Parkinson Disease (PD)","enrollment":100},{"nctId":"NCT00412867","phase":"PHASE4","title":"Post-marketing Clinical Study of Alteplase for Acute Ischemic Stroke （Japan Alteplase Clinical Trial Ⅱ：J-ACT Ⅱ）","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2006-12","conditions":"Stroke","enrollment":58},{"nctId":"NCT05766124","phase":"PHASE2, PHASE3","title":"Trial of Reduced Alteplase Dose for Parapneumonic Effusion (TRAPPE)","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2024-11-01","conditions":"Pleural Infection","enrollment":30},{"nctId":"NCT00147316","phase":"PHASE3","title":"Japan Alteplase Clinical Trial (J-ACT): Efficacy and Safety Study of Tissue Plasminogen Activator (Alteplase) for Ischemic Stroke","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2002-04","conditions":"Cerebral Infarction, Brain Ischemia","enrollment":103},{"nctId":"NCT07256197","phase":"PHASE3","title":"PCSK9 Inhibitors in the Treatment of Calcific Aortic Stenosis","status":"NOT_YET_RECRUITING","sponsor":"Beijing Anzhen Hospital","startDate":"2026-01-01","conditions":"Aortic Stenosis, Calcific","enrollment":160},{"nctId":"NCT06522932","phase":"PHASE1","title":"PET Imaging Study of 64Cu-GRIP B for Patients Receiving CD19-directed CAR-T Therapy","status":"RECRUITING","sponsor":"Michael Randall","startDate":"2024-10-23","conditions":"Non Hodgkin Lymphoma","enrollment":32},{"nctId":"NCT05728333","phase":"PHASE2, PHASE3","title":"Intravenous Tirofiban Versus Alteplase Before Mechanical Thrombectomy in Stroke","status":"RECRUITING","sponsor":"Xinqiao Hospital of Chongqing","startDate":"2023-11-28","conditions":"Stroke, Acute Ischemic","enrollment":800},{"nctId":"NCT06184321","phase":"EARLY_PHASE1","title":"Alteplase Through an Indwelling Pleural Catheter for the Management of Symptomatic Septated Malignant Pleural Effusion","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-08-17","conditions":"Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm","enrollment":30},{"nctId":"NCT06263270","phase":"PHASE1","title":"Evaluation of CYT-108, A Recombinant Protease Inhibitor, for Treatment of Mild To Moderate Primary Osteoarthritis Of The Knee","status":"COMPLETED","sponsor":"Cytonics Corporation","startDate":"2024-06-01","conditions":"Osteoarthritis, Knee, Osteoarthritis","enrollment":19},{"nctId":"NCT05887401","phase":"NA","title":"Physical Activity and Healthy Eating Among Young Adult Cancer Survivors","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2023-10-02","conditions":"Physical Activity, Neoplasms, Cancer","enrollment":72},{"nctId":"NCT06613516","phase":"PHASE2","title":"Effect of Capivasertib on ctDNA in ER Positive Breast Cancer","status":"WITHDRAWN","sponsor":"Imperial College London","startDate":"2025-02-01","conditions":"Breast Cancer, Oestrogen Receptor Positive Breast Cancer","enrollment":""},{"nctId":"NCT05499013","phase":"PHASE1, PHASE2","title":"Study to Assess SLN124 in Patients With Polycythemia Vera","status":"ACTIVE_NOT_RECRUITING","sponsor":"Silence Therapeutics plc","startDate":"2023-01-26","conditions":"Polycythemia Vera","enrollment":69},{"nctId":"NCT04745910","phase":"PHASE4","title":"Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-04-05","conditions":"Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Tumor Lysis Syndrome","enrollment":10},{"nctId":"NCT05009992","phase":"PHASE2","title":"Combination Therapy for the Treatment of Diffuse Midline Gliomas","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2021-10-20","conditions":"Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent Diffuse Intrinsic Pontine Glioma","enrollment":360},{"nctId":"NCT07092709","phase":"PHASE3","title":"Tenecteplase for Intravenous Stroke Thrombolysis in Recent DOAC Users","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-08-14","conditions":"Acute Ischemic Stroke","enrollment":912},{"nctId":"NCT05014984","phase":"NA","title":"WOOP VA: Promoting Weight Management in Primary Care","status":"ACTIVE_NOT_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2022-02-15","conditions":"Obesity","enrollment":405},{"nctId":"NCT04722887","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin Deficiency","status":"COMPLETED","sponsor":"Grifols Therapeutics LLC","startDate":"2021-08-13","conditions":"Alpha1-Antitrypsin Deficiency","enrollment":17},{"nctId":"NCT07214805","phase":"NA","title":"Perceptions of and Reactions to Ultra-Processed Menu Label Designs","status":"COMPLETED","sponsor":"Johns Hopkins Bloomberg School of Public Health","startDate":"2025-10-09","conditions":"Food Choices","enrollment":14720},{"nctId":"NCT05591677","phase":"PHASE2","title":"D-Cycloserine Augmentation of Intermittent Theta Burst Stimulation (iTBS) in Depression (COGENT)","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Alfred","startDate":"2023-04-21","conditions":"Major Depressive Disorder","enrollment":180},{"nctId":"NCT04940052","phase":"PHASE3","title":"Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2021-11-15","conditions":"Differentiated Thyroid Cancer (DTC)","enrollment":153},{"nctId":"NCT00042289","phase":"","title":"Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-06-09","conditions":"HIV Infections","enrollment":1578},{"nctId":"NCT07208097","phase":"NA","title":"Stereotactic Thrombolysis With Tenecteplase for Supratentorial Intracerebral Hemorrhage","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-10-25","conditions":"Intracerebral Haemorrhage, Minimally Invasive Treatment","enrollment":768},{"nctId":"NCT07256171","phase":"","title":"COAST Study - Cholesterol Optimization After Stroke","status":"NOT_YET_RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2026-01-01","conditions":"Stroke (CVA) or Transient Ischemic Attack, Cerebral Hemorrhage","enrollment":500},{"nctId":"NCT06221371","phase":"PHASE3","title":"Endovascular Treatment With or Without Preceding Intravenous Tenecteplase (TNK) in Patients With Late-window acUte Ischemic Stroke Due to Middle Cerebral Artery Occlusion","status":"COMPLETED","sponsor":"Beijing Tiantan Hospital","startDate":"2024-01-25","conditions":"Ischemic Stroke, Acute, Thrombolysis, Endovascular Treatment","enrollment":391},{"nctId":"NCT06196320","phase":"PHASE3","title":"Tenecteplase Reperfusion Therapy in Acute Ischaemic Cerebrovascular Events-5","status":"COMPLETED","sponsor":"Beijing Tiantan Hospital","startDate":"2024-01-24","conditions":"Ischemic Stroke, Acute","enrollment":452},{"nctId":"NCT05631847","phase":"NA","title":"Direct Endovascular Treatment Versus Bridging Treatment In Basilar Artery Occlusive Stroke","status":"COMPLETED","sponsor":"Sichuan Academy of Medical Sciences","startDate":"2023-04-17","conditions":"Acute Ischemic Stroke, Basilar Artery Occlusion, Thrombosis","enrollment":345},{"nctId":"NCT07245147","phase":"NA","title":"REDO-AF: Randomized Evaluation of Dual Options for AF Re-intervention","status":"NOT_YET_RECRUITING","sponsor":"Jacqueline Joza","startDate":"2025-11","conditions":"Atrial Fibrillation (AF), AV Node Ablation, Left Bundle Branch Pacing","enrollment":16},{"nctId":"NCT07241065","phase":"PHASE1","title":"A Study to Investigate the Effect of Capivasertib on the Pharmacokinetics of Oral Dextromethorphan (CYP2D6 Substrate) in Healthy Participants","status":"NOT_YET_RECRUITING","sponsor":"AstraZeneca","startDate":"2026-01-28","conditions":"Healthy Participants","enrollment":35},{"nctId":"NCT00853710","phase":"NA","title":"Test Semiquantitative Prostate Specific Antigen (PSA)","status":"COMPLETED","sponsor":"Institut Curie","startDate":"2009-03","conditions":"Prostate Cancer, Prostatic Neoplasms, Prostatic Diseases","enrollment":94},{"nctId":"NCT07047014","phase":"PHASE3","title":"Advancing Reperfusion Therapy for Ischemic Stroke (ARTS): Tenecteplase in Medium Vessel Occlusion (MeVO) for Acute Ischemic Stroke","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2025-07-30","conditions":"Stroke, Ischemic, Medium Vessel Occlusions","enrollment":596},{"nctId":"NCT06954155","phase":"PHASE3","title":"Tenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-BEYOND","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2025-05-30","conditions":"Stroke","enrollment":330},{"nctId":"NCT06298383","phase":"NA","title":"The Effect of Three Different Medications on Anesthetic Success and Postoperative Pain","status":"RECRUITING","sponsor":"Cairo University","startDate":"2025-06-15","conditions":"Symptomatic Irreversible Pulpitis","enrollment":120},{"nctId":"NCT06807021","phase":"PHASE2, PHASE3","title":"Post-Operative Use of FS2 to Mitigate Scarring in Burn Patients","status":"RECRUITING","sponsor":"Birch BioMed Inc","startDate":"2025-12-01","conditions":"Burn Scar, Burn Wound","enrollment":70},{"nctId":"NCT05400122","phase":"PHASE1","title":"Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer","status":"SUSPENDED","sponsor":"David Wald","startDate":"2022-09-09","conditions":"Colorectal Cancer, Hematologic Malignancy, Rectum Cancer","enrollment":12},{"nctId":"NCT06876129","phase":"PHASE1","title":"Pharmacologic Augmentation of TMS for Depression With D-serine","status":"RECRUITING","sponsor":"Mclean Hospital","startDate":"2025-04-01","conditions":"Depression","enrollment":60},{"nctId":"NCT05469178","phase":"PHASE1, PHASE2","title":"A Clinical Study of Bemcentinib With Standard of Care Chemoimmunotherapy in Untreated Advanced/Metastatic Non-small Cell Lung Cancer Patients With a Mutation in the STK11 Gene","status":"TERMINATED","sponsor":"BerGenBio ASA","startDate":"2023-03-03","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":26},{"nctId":"NCT06008093","phase":"PHASE3","title":"A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-04-04","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":280},{"nctId":"NCT04933695","phase":"PHASE2","title":"A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line Treatment","status":"COMPLETED","sponsor":"Amgen","startDate":"2022-01-28","conditions":"Non-small Cell Lung Cancer","enrollment":42},{"nctId":"NCT06379724","phase":"PHASE4","title":"Burn Study- Tranexamic Acid Versus Thrombin in Split Thickness Skin Graft","status":"RECRUITING","sponsor":"University of Kansas Medical Center","startDate":"2024-07-11","conditions":"Burns, Skin Graft Complications","enrollment":62},{"nctId":"NCT01334827","phase":"NA","title":"A Formative Study to Explore the Sensory Perceptions of Vaginal Product Users","status":"COMPLETED","sponsor":"The Miriam Hospital","startDate":"2011-04","conditions":"Microbicide Delivery System Acceptability","enrollment":48},{"nctId":"NCT02897063","phase":"PHASE1","title":"Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2016-09","conditions":"Autonomic Failure, Pure Autonomic Failure, Multiple System Atrophy","enrollment":34},{"nctId":"NCT02000089","phase":"PHASE3","title":"The Cancer of the Pancreas Screening-5 CAPS5)Study","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2014-01-06","conditions":"Pancreas Cancer, Peutz-Jeghers Syndrome (PJS), Gene Mutation","enrollment":9000},{"nctId":"NCT00873951","phase":"NA","title":"Influence of Protein Hydrolysis on Dietary Protein Digestibility and Metabolism in Healthy Subjects","status":"COMPLETED","sponsor":"Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement","startDate":"2006-01","conditions":"Healthy","enrollment":26},{"nctId":"NCT07205237","phase":"NA","title":"Effect of Eliminating Red Meat Consumption on the Cardiovascular System","status":"COMPLETED","sponsor":"Maria Clara Rocha","startDate":"2023-02-02","conditions":"Cardiovascular (CV) Risk","enrollment":12},{"nctId":"NCT05400733","phase":"NA","title":"Prandial Metabolic Phenotype in Adults","status":"RECRUITING","sponsor":"Texas A&M University","startDate":"2022-06-24","conditions":"Protein Metabolism","enrollment":50},{"nctId":"NCT07198685","phase":"NA","title":"6 Months of Bedaquiline(BDQ), Delamanid(DLM), Linezolid(LZD) and Levofloxacin(LFX) in RR-TB Patients in Hubei Province","status":"NOT_YET_RECRUITING","sponsor":"Wuhan Pulmonary Hospital","startDate":"2025-09-30","conditions":"Treat to Target, Treatment Duration","enrollment":52}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4101,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["amino acid supplementation with L-serine"],"phase":"marketed","status":"active","brandName":"L-Serine","genericName":"L-Serine","companyName":"Elijah W. Stommel","companyId":"elijah-w-stommel","modality":"Small molecule","firstApprovalDate":"","aiSummary":"L-Serine is a non-essential amino acid that serves as a precursor for neurotransmitter and phospholipid synthesis, supporting neurological function and cell membrane integrity. Used for Serine deficiency disorders, Neurological support in various conditions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}